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Abstract
Introduction: The	aim	of	this	study	was	to	describe	trends	in	the	diagnosis	and	treat‐
ment	of	women	referred	from	the	national	screening	program	with	cervical	intraepi‐
thelial	neoplasia	(CIN)	in	the	Netherlands,	and	to	compare	these	trends	with	national	
guidelines	and	identify	potential	areas	for	improvement	for	the	new	primary	high‐risk	
HPV	screening	program.
Material and methods: We	conducted	a	population‐based	cohort	study	using	data	
from	the	Dutch	pathology	archive.	Women	aged	29‐63	years	who	took	part	in	the	
Dutch	cervical	screening	program	between	1	January	2005	and	31	December	2014	
were	selected.	Three	referral	groups	were	identified:	direct	referrals	and	those	re‐
ferred	after	either	one	(first	indirect	referrals)	or	two	(second	indirect	referrals)	re‐
peat	 cytology	 tests,	 totaling	 85	239	 referrals	 for	 colposcopy.	 The	 most	 invasive	
management	technique	and	the	most	severe	diagnosis	of	each	screening	episode	was	
identified.	Rates	of	management	techniques	were	calculated	separately	by	referral	
type,	highest	CIN	diagnosis	and	age	group.
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1  | INTRODUC TION
In	 the	 Netherlands,	 cervical	 intraepithelial	 neoplasia	 (CIN)	 de‐
tection	 rates	 have	 increased	 over	 the	 last	 decade,	 largely	 inde‐
pendent	 of	 the	 socioeconomic	 and	 demographic	 factors.1	 The	
replacement	 of	 conventional	 cytology	 by	 high‐risk	 human	 papil‐
lomavirus	 (hrHPV)	DNA	 testing	 as	 primary	 screening	 test	 in	 the	
Dutch	Cervical	Cancer	Screening	Program	in	2017	will	 likely	fur‐
ther	increase	CIN	detection,	given	the	higher	sensitivity	of	hrHPV	
testing	for	CIN	2+	lesions.2	Recent	Dutch	modeling	estimated	that	
the	number	of	detected	CIN	 lesions	would	 increase	by	196%	for	
CIN	1	and	54%	for	CIN	2	over	the	lifetime	of	women	entering	the	
program	in	2017	due	to	primary	hrHPV	screening.3
As	 more	 CIN	 lesions	 are	 detected,	 there	 is	 concern	 about	
overtreatment,	which	could	result	 in	 increased	harm	associated	
with	 screening.4	 Evidence	 suggests	 that	 there	 is	 an	 association	
between	 excisional	 treatments	 for	 CIN	 and	 adverse	 obstet‐
ric	 outcomes	 including	 preterm	 birth	 and	 low	 birthweight.5,6 
Increasing	 excision	 volume	 has	 been	 associated	with	 increased	
risk.6,7	 Additionally,	 a	 robust	 randomized	 controlled	 trial	 con‐
cluded	that	immediate	side‐effects	of	excisional	treatments	such	
as	discharge	and	pain	occur	more	frequently,	more	severely	and	
for	longer	in	women	treated	with	large	loop	excision	of	the	trans‐
formation	 zone	 (LLETZ)	 compared	 with	 both	 colposcopy‐only	
and	biopsy‐diagnosed	women.8
The	 Dutch	 Association	 of	 Obstetrics	 and	 Gynecology	 has	
published	 consensus‐based	 guidelines	 for	 CIN	 treatment	 and	
management	which	detail	the	recommended	treatment	practices,	
including	 recommending	 no	 treatment	 of	 CIN	 1	 and	 excisional	
treatment	of	CIN	2+.9	However,	compliance	with	these	guidelines	
has	never	been	evaluated.	The	lack	of	evaluation	of	CIN	manage‐
ment	 in	 the	Dutch	 setting	 has	 been	 recognized	 by	 others4 as a 
knowledge	gap	 in	an	otherwise	closely	monitored	program.	Our	
study	intends	to	objectify	current	clinical	management	of	CIN	to	
understand	 discrepancies	 between	 guideline	 recommendations	
and	observed	interventions.	By	doing	so,	we	aim	to	identify	po‐
tential	areas	for	improvement	for	the	new	primary	hrHPV	screen‐
ing	program.
2  | MATERIAL AND METHODS
National	organized	 cervical	 cancer	 screening	has	 taken	place	 in	
the	Netherlands	since	the	1980s.	Women	are	invited	for	cytology	
screening	every	5	years	from	the	ages	30	to	60.	Screening	takes	
place	 within	 primary	 care.	Women	 are	 referred	 to	 a	 gynecolo‐
gist	 when	 colposcopy	 is	 required.	 Details	 of	 clinical	 guidelines	
for	 management	 of	 CIN	 are	 given	 in	 Table	1.	 Since	 1998,	 the	
recommendations	 for	 management	 of	 abnormal	 cytology	 have	
been	 fairly	 stable,	 allowing	 for	 more	 reliable	 measurement	 of	
procedural	 parameters	 after	 colposcopy.	 In	 2017,	 hrHPV	 test‐
ing	 replaced	 cytology	 as	 the	 primary	 screening	 test	 within	 the	
program.10
Our	 study	 is	 a	 population‐based	 cohort	 study.	 Women	 aged	
29‐63	years	who	participated	in	the	national	screening	program	and	re‐
ceived	referral	advice	between	1	January	2005	and	31	December	2014	
were	 included.	 Possible	 referral	 pathways	 within	 the	 Dutch	 screen‐
ing	program	can	be	found	 in	Figure	1.	Three	groups	of	referrals	were	
identified:
Results: In	all,	85.1%	of	CIN	3	lesions	were	treated	with	excision	(either	large	excision	
or	hysterectomy)	and	26.4%	of	CIN	1	lesions	were	treated	with	large	excision.	Rates	
of	overtreatment	(CIN	1	or	less)	in	see‐and‐treat	management	were	higher	for	indirect	
referrals	 than	 for	 direct	 referrals	 and	 increased	with	 age.	 Large	 excision	 rates	 in‐
creased	with	CIN	diagnosis	severity.
Conclusions: Despite	 guideline	 recommendations	 not	 to	 treat,	CIN	1	 lesions	were	
treated	in	just	over	25%	of	cases	and	approximately	15%	of	CIN	3	lesions	were	pos‐
sibly	undertreated.	Given	the	expected	increase	in	CIN	detection	in	the	new	primary	
high‐risk	HPV	screening	program,	reduction	in	CIN	1	treatment	and	CIN	2	treatment	
in	younger	women	is	needed	to	avoid	an	increase	in	potential	harm.
K E Y W O R D S
cervical	cancer	screening,	cervical	intraepithelial	neoplasia,	cohort	study,	treatment	
guidelines,	treatment	of	cervical	dysplasia
Key message
Both	 over‐	 and	 undertreatment	 of	 cervical	 intraepithe‐
lial	 neoplasia	 occurs	 after	 referral	 from	 organized	 cervi‐
cal	 	cancer	screening,	despite	 treatment	guidelines	being	
available.
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•	 Direct	 referrals:	Women	who	 received	 referral	 advice	after	pri‐
mary	 cytology	 of	 high‐grade	 squamous	 intraepithelial	 lesion	
(HSIL)/adenocarcinoma	in	situ	(AIS)/atypical	endometrial	glandu‐
lar	 cells	 (AGC)AGC	 favoring	neoplasia/cancer.	 The	 classification	
ASC‐H	(atypical	squamous	cells	cannot	exclude	HSIL)	 is	not	uti‐
lized	in	the	Netherlands.
•	 First	 indirect	referrals:	Women	who	received	referral	advice	for	
repeat	testing	6	months	after	primary	cytology	of	atypical	squa‐
mous	 cells	 of	 undetermined	 significance	 (ASC‐US)/low‐grade	
squamous	intraepithelial	lesion	(LSIL)	or	endocervical	AGC.
•	 Second	 indirect	 referrals:	Women	who	 received	 referral	 advice	
after	two	triage	cytology	tests	(at	6	and	18	months),	with	the	first	
repeat	cytology	being	negative,	hrHPV‐negative	with	endocervi‐
cal	ASC‐US/LSIL/AGC	or	hrHPV	positive	with	negative	cytology,	
and	second	triage	cytology	being	ASC‐US	or	higher.
We	 excluded	 women	 with	 primary	 smears	 taken	 by	 a	 gy‐
necologist,	 as	 women	 under	 the	 care	 of	 a	 gynecologist	 in	 the	
Netherlands	are	usually	already	receiving	specialist	care.	Indirect	
referrals	 must	 have	 been	 referred	 within	 4	years	 of	 primary	
screening	to	be	 included,	 in	 line	with	the	definitions	used	 in	the	
monitoring	 of	 the	 national	 screening	 program.	 Repeat	 cytology	
testing	 at	 6	months	 could	 be	 performed	 either	 with	 or	 without	
hrHPV	triage.	As	hrHPV	triage	was	not	a	standard	practice	in	all	
pathology	labs	during	the	study	period,	we	did	not	include	hrHPV	
status	information	in	our	study.
There	is	no	national	registry	of	gynecological	treatments	in	the	
Netherlands.	Therefore,	we	used	an	extract	of	all	cervical	cytology	
and	histology	records	from	the	nationwide	network	and	registry	of	
histo‐	and	cyto‐pathology	 in	the	Netherlands	 (PALGA).	PALGA	has	
a	 nationwide	 coverage	 of	 all	 pathology	 labs.11	Women	 are	 identi‐
fied	by	the	first	eight	letters	of	their	surname	(maiden	name	is	used	
for	married	women)	 and	 date	 of	 birth.	 Information	 about	 primary	
screening	as	well	as	up	to	five	follow‐up	cytology	and/or	histology	
samples	were	 selected.	Follow	up	of	primary	 smears	was	 included	
until	the	end	of	the	database—31	March	2016.	We	defined	“episode	
of	screening”	as	the	period	starting	with	the	primary	screening	test,	
possibly	 followed	 by	 follow‐up	 tests	 and/or	 treatment	 and	 ending	
with	the	next	primary	cytology	in	the	database.	We	only	analyzed	in‐
formation	recorded	during	this	window	(see	Appendix	S1).	As	PALGA	
is	not	a	registry	of	treatments,	we	validated	our	results	with	two	ex‐
pert	 groups	and	with	 clinical	data	 from	one	gynecology	clinic	 (see	
Appendix	S2).
Our	primary	outcome	measure	was	the	proportion	of	the	most	
invasive	diagnostic	tests	and	therapeutic	treatments	by	the	most	se‐
vere	CIN	diagnosis	within	a	screening	episode.	Our	secondary	out‐
come	measure	was	the	proportion	of	overtreatment	in	see‐and‐treat	
management.	The	most	severe	diagnosis	within	 the	screening	epi‐
sode	was	identified	from	all	diagnostic	codes	recorded	after	referral	
advice	as	follows:	most	to	least	severe—cancer,	CIN	3;	CIN	2,	CIN	1,	
benign/reactive,	cytology	only,	no	diagnosis	recorded.
Diagnostic	 tests	 and	 therapeutic	 treatments	 are	 pre‐coded	 by	
PALGA.	The	most	aggressive	test/treatment	of	the	episode	after	re‐
ferral	was	ranked	as	follows:	most	to	least	aggressive‐‐hysterectomy,	
large	excision	 (including	cone	biopsy,	LLETZ,	other	excisional	 treat‐
ments),	polypectomy,	endometrial	curettage,	endocervical	curettage,	
punch	 biopsy	 (excluding	 cone	 biopsy),	 cytology	 only,	 other	 tech‐
niques.	This	ranking	was	verified	by	gynecologists	and	pathologists.
TA B L E  1  Summary	of	Dutch	CIN	treatment	guidelines
2004 Guidelines9 2015 Guidelines21
Histological	
diagnosis at 
colposcopy
Targeted	biopsies	are	required	only	with	
an	atypical	transformation	zone
Biopsy	can	be	omitted	if	there	is	slight	cytological	dysplasia	and	no	visible	
colposcopic	abnormalities,	in	situations	when	the	whole	transformation	zone	
can	be	seen.	At	least	two	random	biopsies	should	be	taken	where	there	are	
severe	cytological	abnormalities	with	no	colposcopic	abnormalities.	In	the	
case	of	severe	cytological	and	colposcopic	abnormalities,	either	two	targeted	
biopsies	can	be	taken	or	“see‐and‐treat”	management	can	be	used.
CIN	1 Generally	not	treated In	principle,	should	not	be	treated.	In	the	case	of	persistent	low‐grade	cytology	
outside	of	reproductive	age,	treatment	options	may	be	discussed	with	the	
patient.
CIN	2 Should	be	treated,	preferably	by	LLETZa  Individual	assessment	is	required,	particularly	in	younger	women,	weighing	up	
the	risks	and	benefit	of	treatment.	If	treatment	is	decided	on,	LLETZa 	is	
recommended.
CIN	3 Should	be	treated,	preferably	by	LLETZa  Should	always	be	treated.	Women	with	high‐grade	cytology	(moderate	
dyskaryosis/dysplasia	or	worse)	and	colposcopy	are	eligible	for	see‐and‐treat	
management.	LLETZa 	recommended.
Glandular	disease Conization	is	preferred	if	there	is	
suspicion	of	AIS
It	should	be	discussed	with	the	patient	whether	she	wants	an	excisional	
treatment	or	hysterectomy,	provided	that	invasive	carcinoma	is	excluded	as	
far	as	possible.	Conization	is	preferred	for	AIS	as	it	allows	for	better	
assessibility	of	the	endocervical	area	and	margins.	If	LLETZ	is	chosen,	the	
pathologist	must	be	notified	for	a	better	assessment	of	the	margins.
CIN,	cervical	intraepithelial	neoplasia;	LLETZ,	large	loop	excision	of	the	transformation	zone;	AIS,	adenocarcinoma	in	situ.
aLarge	loop	excision	of	the	transformation	zone.	
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See‐and‐treat	management	involves	combining	colposcopy	and	
treatment	in	the	same	outpatient	visit.12	A	large	excision	in	the	next	
record	 after	 referral	 was	 considered	 indicative	 of	 see‐and‐treat	
management.	 We	 estimated	 possible	 overtreatment	 in	 see‐and‐
treat	management	as	the	proportion	of	women	with	CIN	1	or	lower	
histological	diagnosis	as	the	highest	diagnosis	of	the	episode	who	
were	treated	by	large	excision	at	the	first	contact	with	a	gynecol‐
ogist,	divided	by	all	women	who	were	treated	by	large	excision	at	
the	first	contact	with	a	gynecologist	(definition	from	Ebisch	et	al12).	
Age	at	primary	screening	was	grouped	into	5‐year	age‐groups.
2.1 | Statistical analyses
Chi‐square	 tests	 were	 performed	 to	 compare	 differences	 be‐
tween	 proportions.	 Analysis	 of	 variance	 was	 used	 to	 compare	
mean	ages	across	referral	types.	For	one‐way	tables,	a	chi‐square	
goodness	of	fit	test	was	applied.	Confidence	intervals	for	propor‐
tions were calculated using a binomial distribution. All analyses 
were	performed	using	SAS	Base	v9.4	(SAS	Institute	Inc.,	Cary,	NC,	
USA).
2.2 | Ethical approval
We	 used	 a	 retrospective,	 anonymized	 dataset	 from	 PALGA,	
which	is	exempt	from	ethical	approval	by	a	Medical	Ethics	Testing	
Committee.	We	obtained	anonymized	clinical	data	(only	women	
referred	 from	the	national	 screening	program)	 for	validation	as	
part	of	 the	evaluation	of	the	national	cervical	cancer	screening	
program	(evaluation	of	national	screening	programs	is	legislated	
in	the	Population	Screening	Act	in	the	Netherlands).	We	received	
F I G U R E  1  Pathways	to	referral	within	the	Dutch	Cervical	Cancer	Screening	Program,	adapted	from	Bekkers	et	al31	and	Rozemeijer.32 
*Includes	HSIL,	AGC	endometrial,	AGC	favoring	neoplasia,	adenocarcinoma	in	situ	and	cancer	irrespective	of	hrHPV	status.	**Includes	
ASC‐US,	LSIL,	AGC	endometrial	and	HSIL	or	worse*	cytology	results.	ASC‐US/LSIL,	atypical	squamous	cells	of	undetermined	significance/
low‐grade	squamous	intraepithelial	lesion;	AGC,	atypical	glandular	cells;	HSIL,	high‐grade	squamous	intraepithelial	lesion
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written	approval	from	the	Medical	Director	of	the	specialist	out‐
patient	clinic	to	use	their	clinical	data	for	research	purposes.
3  | RESULTS
From	 the	 5	450	148	 primary	 cytology	 smears	 taken	 within	 the	
screening	 program	 from	women	 aged	 29‐63	years	 between	 2005	
and	2014,	98.9%	were	taken	by	a	non‐gynecologist	and	were	eligi‐
ble	for	inclusion	(n	=	5	389	342).	Of	these	smears,	44	209	(0.8%)	re‐
sulted	in	a	direct	referral	to	a	gynecologist,	34	282	(0.6%)	resulted	in	
a	first	indirect	referral	and	6748	(0.1%)	resulted	in	a	second	indirect	
referral	(Table	2).	The	majority	of	referrals	were	within	reproductive	
age	range	(29‐43	years:	65.5%).	The	number	of	referrals	was	higher	
in	2010‐2014	than	in	2005‐2009	for	all	referral	types	(Table	2).
Of	all	women	directly	referred,	81.1%	were	diagnosed	with	a	
CIN	lesion	(that	 is	CIN	1,	2	or	3)	within	the	episode	of	screening	
(Table	2).	The	proportion	of	indirectly	referred	women	diagnosed	
with	a	CIN	lesion	was	lower,	64.9%	for	first	indirect	referrals	and	
39.9%	 for	 second	 indirect	 referrals	 (Table	2).	When	 restricted	 to	
referrals	that	resulted	in	a	histological	diagnosis	(i.e.	excluding	ep‐
isodes	with	 no	 recorded	 diagnosis	 or	 no	 histology	 taken),	 there	
were	 still	 differences	 in	 the	 proportion	 of	 episodes	 diagnosed	
with	a	CIN	lesion	between	the	referral	groups	(direct:	88.7%;	first	
indirect:	78.1%;	second	 indirect:	67.0%)	and	the	difference	were	
statistically	 significant	 (χ2	 [2,	 n = 72	902]	=	2161.98,	 P < 0.001)	
(figures	not	presented).	Among	direct	referrals,	there	was	a	higher	
proportion	of	women	with	a	CIN	3	diagnosis	(53.5%)	than	among	
indirect	 referrals	 (first	 indirect:	 17.5%;	 second	 indirect:	 8.8%)	
(Table	2).
The	 highest	 proportion	 of	 CIN	 lesions	 were	 diagnosed	 in	
women	 aged	 29‐33	years;	 79.8%	 of	 all	 the	 referrals	 in	 this	 age	
group	were	diagnosed	with	a	CIN	lesion	(Figure	2).	The	proportion	
of	episodes	with	no	recorded	diagnosis	or	no	histology	increased	
Variable Direct referrals First indirect referrals Second indirect referrals P
N % N % N %
Total referrals 44 209 34 282 6 748
Total unique woman IDa  43 827 34 081 6	725
Age
Mean	age 39.16 SD:	8.58 39.54	 SD: 8.49 41.35	 SD: 8.74 < 0.001
29–33 12	452	 28.2% 9 086 26.5% 1	352 20.0% < 0.001
34–38 9 373 21.2% 6 661 19.4% 1 117 16.6%
39–43 8	151 18.4% 6	351 18.5% 1	250 18.5%
44–48 6 027 13.6% 5	448 15.9% 1 196 17.7%
49–53 3 944 8.9% 3	567 10.4% 1	005 14.9%
54–58 2	527 5.7% 2 022 5.9% 513 7.6%
59–63 1	735 3.9% 1 147 3.4% 315 4.7%
Period
2005–2009 20 630 46.7% 14 400 42.0% 2 803 41.5% < 0.001
2010–2014 23	579 53.3% 19 882 58.0% 3	945 58.5%
Highest diagnosis of the episode after referral
No	recorded	diagnosis 1 770 4.0% 1	275 3.7% 835	 12.4% < 0.001
Cytology	only 2 023 4.6% 4	540 13.2% 1 894 28.1%
Benign/Otherb  3 019 6.8% 6 072 17.7% 1 306 19.4%
CIN	1 4 039 9.1% 9 024 26.3% 1 411 20.9%
CIN	2 8	152 18.4% 7 219 21.1% 688 10.2%
CIN	3 23 649 53.5% 5	996 17.5% 594 8.8%
Cancerc  1	557 3.5% 156 0.5% 20 0.3%
See	Figure	1	for	description	of	referral	types.
SD:	Standard	deviation;	CIN:	Cervical	intraepithelial	neoplasia.
aSome	IDs	have	more	than	one	referral	within	the	same	referral	type.	The	number	of	unique	IDs	represents	the	number	of	individual	women	referred	
within	the	referral	type.	
bBenign/Other	includes	histological	results	that	are	lower	grade	than	CIN	1.	
cIncludes	micro‐invasive	and	invasive	disease.	
TA B L E  2  Demographic	characteristics	of	women	referred	for	colposcopy	following	participation	in	the	Dutch	cervical	cancer	screening	
program,	all	referral	types,	2005–2014,	rounded	percentages
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with	age	 (Figure	2).	 In	women	aged	44	years	and	older,	61.3%	of	
the	 no	 recorded	 diagnosis	 and	 55.3%	 of	 the	 no	 histology	 group	
had	 no	 further	 primary	 screening	 episodes	 after	 referral.	 The	
remainder	had	further	cytology	and/or	histology	tests	taken	in	the	
next	primary	episode,	which	were	excluded	from	analysis	(figures	
not	presented).
F I G U R E  2  Highest	diagnosis	of	the	
screening	episode	within	age	groups,	all	
women	referred,	rounded	percentages.	
*	Includes	micro‐invasive	and	invasive	
disease.	CIN,	cervical	intraepithelial	
neoplasia
CIN I (%) CIN 2 (%) CIN3 (%) P
Direct	referrals
Hysterectomy 1.2 1.8 3.4 <0.001
Large	excisiona  34.4 69.4 82.0
Biopsyb  62.5 28.2 14.3
Other	techniquesc  1.9 0.6 0.3
First	indirect	referrals
Hysterectomy 0.9 1.7 2.9 <0.001
Large	excisiona  23.9 66.9 81.3
Biopsyb  73.2 30.8 15.4
Other	techniquesc  1.9 0.6 0.4
Second	indirect	referral
Hysterectomy 0.6 2.2 1.9 <0.001
Large	excisiona  19.7 61.8 80.3
Biopsyb  77.5 35.3 17.3
Other	techniquesc  2.2 0.7 0.5
All	referrals
Hysterectomy 1.0 1.8 3.3 <0.001
Large	excisiona  26.4 68.0 81.8
Biopsyb  70.7 29.7 14.6
Other	techniquesc  1.9 0.6 0.3
See	Figure	1	for	description	of	referral	types.
aLarge	excision	includes	cone	biopsy,	LLETZ	and	other	excisional	therapies.	
bIncludes	all	types	of	biopsies	(excluding	cone	biopsy).	
cIncludes	 polypectomy,	 endometrial	 and	 endocervical	 curettage,	 and	 histology	 not	 otherwise	
specified.	
TA B L E  3  Most	invasive	management	
technique	of	the	screening	episode	by	
most	severe	CIN	diagnosis	of	the	
screening	episode,	rounded	percentages
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The	more	 severe	 the	CIN	diagnosis,	 the	higher	 the	proportion	
of	women	treated	with	a	large	excision	(Table	3).	Women	who	were	
directly	referred	and	diagnosed	with	CIN	1	had	higher	rates	of	large	
excision	treatment	compared	with	women	who	were	 indirectly	re‐
ferred:	34.4%	vs	23.9%	(first	 indirect)	and	19.7%	(second	 indirect);	
χ2	(2,	n = 14	474)	=	193.1,	P < 0.001).	No	age‐dependency	was	seen	
in	the	percentage	with	large	excision	treatment	of	CIN	3	(figures	not	
shown).	For	CIN	1	 lesions,	 the	proportion	of	 treatment	with	 large	
excision	increased	with	age.	Rates	of	treatment	with	large	excision	
differed	 significantly	 between	 referral	 types	 across	 all	 age	 groups	
for	CIN	1	lesions	(from	13.1%	to	50.4%)	and	for	the	four	youngest	
age	groups	for	CIN	2+	lesions	(Figure	3).
See‐and‐treat	management	was	 observed	more	 often	 in	 direct	
referrals	than	indirect	referrals	and	was	performed	mostly	in	women	
with	 severe	CIN	 lesions	 (Figure	4).	Treatment	of	CIN	1	or	 lower,	 in	
see‐and‐treat	 management	 increased	 with	 age	 across	 all	 referral	
types	and	were	higher	for	indirect	referrals	in	all	age	groups	(Figure	5).
4  | DISCUSSION
Despite	 recommendations	 not	 to	 treat	 CIN	 1	 lesions,	 we	 found	
that	26.4%	of	the	diagnosed	CIN1	lesions	underwent	an	excisional	
procedure,	 ranging	 from	 13.2%	 to	 50.4%	 depending	 on	 age	 and	
referral	 type.	Compared	with	the	European	guidelines	 for	clinical	
management	of	abnormal	cervical	cytology,13	the	Dutch	CIN	1	ad‐
vice	 in	the	2004	Guidelines	was	quite	conservative.	Despite	this,	
the	proportion	of	CIN	1	treated	by	large	excision	is	slightly	higher	
than	previously	reported	figures	from	Italian	colposcopy	audits14,15 
with	 the	 latest	 reporting	 that	16%	of	CIN	1	 lesions	were	 treated	
and	that	there	was	an	increase	in	the	proportion	of	CIN	1	that	was	
not	 treated	between	audit	periods.	However,	 compared	with	 the	
European	 Federation	 for	 Colposcopy	 guidelines16	 that	 state	 that	
85%	of	 the	 excisional	 treatments	 should	 have	 a	 definitive	 histol‐
ogy	of	CIN	2+,	our	data	show	that	the	Dutch	program	exceeds	this	
benchmark,	at	87%.	To	our	knowledge,	no	other	European	coun‐
tries	have	published	CIN	treatment	 rates	by	diagnosis	 in	peer‐re‐
viewed	 journals,	 though	 Danish	 researchers	 have	 recommended	
monitoring	of	CIN	treatment	trends	 in	 light	of	the	 increasing	CIN	
treatment	rates	in	Denmark.17
Monitoring	 of	 treatment	 rates	 can	 have	 a	 positive	 effect	 on	
compliance	 with	 guidelines	 by	 making	 practitioners	 cognizant	 of	
recommendations.	A	study	from	one	US	hospital	found	that	active	
monitoring	of	excisional	 treatments	 led	to	an	 increase	 in	guideline	
compliance	and	a	decrease	in	inappropriate	excisional	treatments.18 
Regular	monitoring	should	be	implemented	given	the	expected	rise	
in	CIN	1	diagnoses,	due	to	the	new,	more	sensitive	hrHPV	primary	
test.	Modeling	 estimated	 that	CIN	1	 diagnoses	will	 approximately	
double	in	the	new	screening	program.3	In	the	old	cytology	screening	
program,	if	the	CIN	1	treatment	rate	was	5%	during	the	period	of	our	
study,	rather	than	26.4%,	this	would	have	resulted	in	approximately	
300	fewer	CIN	1	lesions	treated	by	large	excision	per	year.	Under	the	
new	hrHPV	screening	program,	the	impact	of	reduced	CIN	1	treat‐
ment rates could be even larger.
It	is	unrealistic	to	expect	no	CIN	1	treatment,	as	there	will	always	
be	women	with	persistent	or	recurring	low‐grade	abnormalities	for	
whom	 treatment	may	be	 favorable	 or	 reassuring.19	Guidelines	 are	
only	 one	 factor	 in	 clinical	 decision	making	 for	 CIN;	 gynecologists	
consider	 information	 about	 colposcopy,	 cytology,	 hrHPV	 status,	
family	planning,	age,	women's	preferences	and	other	factors	when	
advising	 about	 treatment.	 Communication	 between	 pathologists	
and	gynecologists	also	influences	treatment	decisions.18	There	may	
be	situations	where	CIN	1	would	have	been	preceded	by	HSIL	cy‐
tology,	hrHPV	positivity	and	CIN	2+	colposcopic	 impression	or	bi‐
opsies.	 Additionally,	 in	 women	 with	 transformation	 zone	 type	 3,	
diagnostic	 LLETZ	 after	 high‐grade	 cytology	 is	 indicated	 in	 IARC	
F I G U R E  3  Proportion	of	episodes	
with	large	excision	as	most	aggressive	
treatment	for	CIN	1	and	CIN	2+	
(denominator:	total	episodes	within	
each	age	group	with	the	same	highest	
diagnosis),	by	age	group	and	referral	type.	
*Pearson's	chi‐square	test	significantly	
different	between	referral	types.	See	
Figure	1	for	description	of	referral	types.	
CIN,	cervical	intraepithelial	neoplasia
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guidelines.20	 In	 such	 situations,	 performing	 LLETZ	may	be	 a	 justi‐
fiable,	 appropriate	 treatment.	Clarification	of	 a	 reasonable	 rate	 of	
treatment	 for	CIN	1	 should	be	given	 in	 future	guideline	 revisions,	
preferably	accompanied	by	intuitive	nomograms	to	assist	in	decision	
making,	for	example,	that	hrHPV	negative	biopsies	can	be	observed	
rather	than	treated.
The	treatment	guidelines	were	revised	in	201521 and now advise 
see‐and‐treat	 for	a	 subcategory	of	women.	Although	 this	approach	
has	advantages	(reduced	loss	to	follow	up,	convenience	for	women,	
lower	costs),22	overtreatment	is	a	risk.23	See‐and‐treat	needs	careful	
implementation	to	reduce	overtreatment	risks.	We	found	that	treat‐
ment	of	women	diagnosed	with	CIN	1	or	 lower	was	more	frequent	
in	 indirect	 referrals	 than	 direct	 referrals,	 and	 increased	 with	 age.	
These	 findings	are	 similar	 to	 those	of	other	Dutch	 studies.24	Given	
the	higher	number	of	CIN	1	and	lower	diagnoses	in	the	two	indirect	
referral	groups,	this	finding	is	unsurprising.	Our	results	are	consistent	
F I G U R E  4  Proportion	of	episodes	
managed	with	see‐and‐treat*	within	each	
CIN	diagnosis	group	and	referral	type,	
2005‐2014.	*See‐and‐treat	management	
is	defined	as	episodes	where	the	first	
treatment	after	referral	advice	is	large	
excision.	See	Figure	1	for	description	of	
referral	types
F I G U R E  5  Proportion	of	
overtreatment*	in	see‐and	treat	
management	by	age	group	and	referral	
type.	*Overtreatment	in	see‐and‐treat	
management	is	defined	as	the	proportion	
of	women	with	a	CIN	1	or	lower	
histological	diagnosis	who	were	treated	
with	large	excision	at	the	first	contact	
with	a	gynecologist,	divided	by	all	women	
who	were	treated	with	large	excision	at	
the	first	contact	with	a	gynecologist.	See	
Figure	1	for	description	of	referral	types.	
CIN,	cervical	intraepithelial	neoplasia
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with	Ebisch	and	colleagues12,	who	found	that	women	with	low‐grade	
cytology	had	higher	overtreatment	rates	compared	with	women	with	
high‐grade	cytology.12Restricting	see‐and‐treat	to	women	with	con‐
cordant	 high‐grade	 cytology	 and	 colposcopy	 could	 minimize	 over‐
treatment,	as	could	the	use	of	a	grading	system,	such	as	the	Swede	
score,	which	has	shown	to	have	high	specificity	for	CIN	2+	lesions.25
It	 is	 not	 surprising	 that	 the	 rates	 of	 treatment	with	 large	 exci‐
sion	 for	CIN	2+	 lesions	vary	 little	by	age	within	 referral	 types.	Up	
until	 2015,	 treatment	 guidelines	 for	 CIN	 2	 were	 not	 age‐specific.	
However,	 the	 2015	Guidelines21	 state	 that	women	with	CIN	2	 le‐
sions	should	be	individually	assessed	as	to	whether	the	benefits	of	
treatment	outweigh	the	risks,	largely	related	to	future	childbearing.	
Active	 surveillance	of	 young	women	allows	 time	 for	CIN	2	 lesions	
to	regress,	which	is	likely	to	occur	in	most	CIN	2	cases.26	However,	
active	surveillance	also	comes	with	 the	risk	of	 loss	 to	 follow	up	or	
progression	to	a	higher	grade	lesion.	Going	forward,	we	expect	that	
CIN	2	treatment	will	vary	by	age,	as	more	young	women	are	conser‐
vatively	managed.	As	such,	both	treatment	and	outcomes	for	women	
with	CIN	2	lesions	should	be	monitored	to	ensure	that	clinical	prac‐
tice	reflects	guidelines.
As	expected,	women	diagnosed	with	CIN	3	had	the	highest	rates	
of	treatment	with	excisional	techniques.	This	is	consistent	across	re‐
ferral	types	with	no	differences	by	age	(figures	not	shown).	On	the	
other	hand,	between	14.6%	and	17.8%	of	the	women	diagnosed	with	
CIN	3	were	not	managed	with	an	excisional	treatment	(large	excision	
or	hysterectomy).	This	apparent	undertreatment	may	be	the	result	
of	 several	 factors.	 Although	 uncommon	 in	 the	Netherlands,	 these	
women	may	have	been	 treated	non‐invasively	using	electrocoagu‐
lation,	cryotherapy	or	imiquimod	prescription,	and	these	procedures	
are	not	recorded	in	PALGA.	Undertreatment	may	be	overestimated	
due	 to	 data	 issues,	 such	 as	 records	 belonging	 to	 one	 woman	 not	
being	 properly	 linked.	 Finally,	 a	 clinician	 can	 decide	 to	 use	 an	 ex‐
pectant	management	strategy	if	diagnostic	biopsy	removed	most	of	
the	lesion.	Regardless,	guidelines	state	that	CIN	3	should	always	be	
treated	given	the	risks	of	progression;	long‐term	follow	up	of	women	
in	 an	unethical	 study	 in	which	 treatment	was	delayed	or	withheld	
from	women	with	high‐grade	lesions	showed	that	the	cumulative	in‐
cidence	of	 cervical	 or	 vaginal	 vault	 cancer	was	31.3%	at	30	years,	
with	a	higher	cumulative	incidence	(50.3%)	among	women	with	per‐
sistent	high‐grade	lesions.27	Timely	and	effective	treatment	of	CIN	
3	 is	 therefore	 necessary	 to	 avoid	 the	 risk	 of	 disease	 progression.	
Communication	of	these	results	directly	to	gynecologists	is	essential,	
emphasizing	that	the	benefits	of	treatment	for	these	women	greatly	
outweigh	the	risks.
Our	study	 is	 the	 first	 to	use	a	national	database	 to	 investigate	
CIN	 treatment	practices	 in	 the	Netherlands.	Analysis	 in	 this	 study	
was	 split	 by	 referral	 type,	 allowing	 us	 to	 investigate	women	with	
different	risk	profiles	separately,	as	the	severity	of	the	initial	cytol‐
ogy	 influences	follow	up.	Reflective	of	this,	we	found	that	women	
who	are	directly	referred	have	a	much	higher	proportion	of	CIN	3	
diagnoses.
Our	study	has	some	limitations.	We	did	not	include	information	
about	hrHPV	status	in	our	analysis,	as	the	practice	of	hrHPV	testing	
was	not	universally	conducted	during	the	study	period.	However,	
knowledge	of	hrHPV	status	may	have	resulted	in	more	aggressive	
treatment	for	women	who	were	hrHPV	positive.	We	were	also	un‐
able	to	evaluate	conization	and	large	loop	excisions	separately,	or	
analyze	 by	 depth	 of	 excision	 or	 lesion	 size.	 This	 is	 not	 coded	 in	
PALGA.	This	 information	would	be	useful	 for	stratification	of	 re‐
sults,	as	depth	of	excision	can	have	implications	for	both	the	risk	of	
adverse obstetric outcomes5,6,28	and	the	risk	of	recurrent	or	pro‐
gressive disease.29	Furthermore,	we	do	not	have	information	about	
the	results	of	colposcopy.	If	a	woman	is	referred	to	a	gynecologist	
and	examined	with	colposcopy,	but	has	no	accompanying	 test	or	
treatment,	no	information	is	reported	to	PALGA.
Validation	 of	 our	 results	 with	 clinical	 data	 found	 that	 PALGA	
may	slightly	overestimate	CIN	1	treatments	(Appendix	S2),	although	
these	 clinical	 data	 came	 from	 a	 highly	 specialized	 clinic	with	 phy‐
sicians	 who	 almost	 exclusively	 treat	 cervical	 dysplasia.	 As	 such,	
treatment	of	CIN	1	with	excision	at	this	clinic	is	likely	to	occur	less	
often	than	the	average.	One	Dutch	study	compared	the	 impact	of	
different	 CIN	 management	 strategies	 (more‐or‐less	 aggressive)	 in	
two	hospital	facilities	in	the	same	city	and	found	that	68%	fewer	CIN	
1	lesions	were	found	with	the	less	aggressive	strategy.30	As	PALGA	
has	national	 coverage,	 the	 treatment	 rates	we	observed	were	not	
influenced	by	the	policies	or	practices	of	any	single	clinic.
PALGA	does	not	have	a	unique	identification	code	to	track	wom‐
en's	screening	history;	women	are	identified	by	the	first	eight	letters	
of	their	surname	and	date	of	birth.	It	is	possible	that	tests	of	multiple	
women	are	attributed	to	a	single	identification	code.	In	such	cases,	
it	 is	 possible	 that	 follow	up	was	 censored	 early	 for	 some	women,	
leading	 to	 a	misclassification	of	 the	highest	 diagnosis	 or	 the	most	
invasive	treatment	of	the	episode.
5  | CONCLUSION
Our	study	shows	that	both	under‐	and	overtreatment	take	place,	de‐
spite	guidelines	being	available.	Regular	monitoring	of	national	trends	
and	reviews	of	treatment	rates	should	be	implemented	at	each	clinic	
that	treats	women	for	CIN,	to	make	both	gynecologists	and	patholo‐
gists	aware	of	the	guidelines	and	their	own	performance	in	relation	
to	 them.	This	may	 lead	 to	greater	 compliance	with	 the	guidelines,	
reducing	potential	harm	to	women	referred	from	screening.
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